BALAXI PHARMACEUTICALS LIMITED — Others, 05-11-2024: Appointment

Balaxi Pharmaceuticals Limited's Board approved unaudited financial results for Q2 FY2024, reporting a revenue from operations of ₹211.55 lakhs. The company also announced the resignation of its Company Secretary, Mr. Mahesh Inani, effective November 5, 2024, and appointed Mr. Mohith Khandelwal as his successor, effective November 6, 2024. The detailed financial results and updates will be available on the company's website.